{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:42:57Z","timestamp":1793814177951,"version":"4.6.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Linezolid-induced thrombocytopenia (LIT) occurs in a dose-dependent manner. There is no consensus regarding personalized dosing of linezolid in the real world. This study investigated the usefulness of personalized dosing for the potential mitigation of LIT compared with standard dosing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic review and meta-analysis were performed using 4 medical electronic databases. Inclusion criteria were original research articles published up to October 23, 2023, whereas nonoriginal articles were excluded. Eligible participants included adults who were administered linezolid. A random-effects model was used to synthesize the results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Four studies were eligible for inclusion. There were 208 patients in the personalized dosing (intervention) group and 195 patients in the standard dosing (comparison) group. The odds ratio for the intervention was 0.648 (95% confidence interval: 0.150\u20132.797), although significant heterogeneity was observed (<jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> = 83.3%). An ad hoc analysis was performed by excluding one study with a significant bias risk in the treatment duration. The odds ratio for the intervention in the ad hoc analysis was 0.356 (95% confidence interval: 0.179\u20130.708) with little heterogeneity, showing a lower incidence risk of LIT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Personalized dosing in linezolid therapy may mitigate the risk of LIT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001300","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T10:00:08Z","timestamp":1737626408000},"page":"529-536","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Personalized Dosing of Linezolid to Reduce the Risk of Thrombocytopenia: A Systematic Review and Meta-Analysis"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0693-1896","authenticated-orcid":false,"given":"Kazutaka","family":"Oda","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Tsuruta","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences ,Kumamoto University, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hanai","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Narashino Campus, Toho University, Funabashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kitasato University Hospital, Sagamihara, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences ,Kumamoto University, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Jono","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan;"},{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences ,Kumamoto University, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan;"},{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences ,Kumamoto University, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"R1-20250711","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/AAC.42.12.3251","article-title":"The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria","volume":"42","author":"Swaney","year":"1998","journal-title":"Antimicrob Agents Chemother."},{"key":"R2-20250711","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/j.1875-9114.1998.tb03109.x","article-title":"The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials","volume":"18","author":"Dresser","year":"1998","journal-title":"Pharmacotherapy."},{"key":"R3-20250711","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1128\/AAC.41.10.2132","article-title":"Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions","volume":"41","author":"Shinabarger","year":"1997","journal-title":"Antimicrob Agents Chemother."},{"key":"R4-20250711","first-page":"CD008056","article-title":"Linezolid versus vancomycin for skin and soft tissue infections","volume":"2016","author":"Yue","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"R5-20250711","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3390\/antibiotics12040697","article-title":"Effectiveness and safety of linezolid versus vancomycin, teicoplanin, or daptomycin against methicillin-resistant Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"12","author":"Kawasuji","year":"2023","journal-title":"Antibiotics (Basel)."},{"key":"R6-20250711","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1128\/AAC.49.9.3676-3681.2005","article-title":"Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings","volume":"49","author":"Beringer","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"R7-20250711","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11096-021-01342-y","article-title":"Risk factors for linezolid-induced thrombocytopenia in adult inpatients","volume":"44","author":"Han","year":"2022","journal-title":"Int J Clin Pharm."},{"key":"R8-20250711","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bcpt.13123","article-title":"Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases","volume":"124","author":"Choi","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R9-20250711","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jiac.2016.05.003","article-title":"A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia","volume":"22","author":"Hanai","year":"2016","journal-title":"J Infect Chemother."},{"key":"R10-20250711","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/bcp.13262","article-title":"Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients","volume":"83","author":"Tsuji","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"R11-20250711","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/14656566.2016.1182154","article-title":"Risk factors associated with high linezolid trough plasma concentrations","volume":"17","author":"Morata","year":"2016","journal-title":"Expert Opin Pharmacother."},{"key":"R12-20250711","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents."},{"key":"R13-20250711","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1128\/AAC.01885-13","article-title":"Clinical population pharmacokinetics and toxicodynamics of linezolid","volume":"58","author":"Boak","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R14-20250711","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10096-013-2041-3","article-title":"Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients","volume":"33","author":"Dong","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"R15-20250711","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet."},{"key":"R16-20250711","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R17-20250711","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bcp.12806","article-title":"A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?","volume":"81","author":"Pea","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"R18-20250711","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2016.08.023","article-title":"Therapeutic drug management of linezolid: a missed opportunity for clinicians?","volume":"48","author":"Cattaneo","year":"2016","journal-title":"Int J Antimicrob Agents."},{"key":"R19-20250711","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/jac\/dkz374","article-title":"Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study","volume":"74","author":"Cojutti","year":"2019","journal-title":"J Antimicrob Chemother."},{"key":"R20-20250711","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/1120009X.2022.2043538","article-title":"Initial trough concentration may be beneficial in preventing linezolid-induced thrombocytopenia","volume":"34","author":"Komatsu","year":"2022","journal-title":"J Chemother."},{"key":"R21-20250711","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med."},{"key":"R22-20250711","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"R24-20250711","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ."},{"key":"R25-20250711","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med."},{"key":"R26-20250711","doi-asserted-by":"crossref","first-page":"106881","DOI":"10.1016\/j.ijantimicag.2023.106881","article-title":"Dose optimisation of linezolid in critically ill patients based on a population pharmacokinetic model: a two-centre prospective interventional study","volume":"62","author":"Shi","year":"2023","journal-title":"Int J Antimicrob Agents."},{"key":"R27-20250711","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/antibiotics10050496","article-title":"Initially reduced linezolid dosing regimen to prevent thrombocytopenia in hemodialysis patients","volume":"10","author":"Kawasuji","year":"2021","journal-title":"Antibiotics (Basel)."},{"key":"R28-20250711","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40360-021-00479-w","article-title":"Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients","volume":"22","author":"Kawasuji","year":"2021","journal-title":"BMC Pharmacol Toxicol."},{"key":"R29-20250711","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2014.01.012","article-title":"Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight","volume":"79","author":"Niwa","year":"2014","journal-title":"Diagn Microbiol Infect Dis."},{"key":"R30-20250711","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00228-023-03542-z","article-title":"Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis","volume":"79","author":"Zhang","year":"2023","journal-title":"Eur J Clin Pharmacol."},{"key":"R31-20250711","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1248\/bpb.b19-00154","article-title":"Coefficient of determination between estimated and measured renal function in Japanese patients with sarcopenia may be improved by adjusting for muscle mass and sex: a prospective study","volume":"42","author":"Nakatani","year":"2019","journal-title":"Biol Pharm Bull."},{"key":"R32-20250711","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1186\/s12879-023-08831-7","article-title":"Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more","volume":"23","author":"Xu","year":"2023","journal-title":"BMC Infect Dis."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T12:01:13Z","timestamp":1752235273000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001300","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"2024-08-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}